Long-term Follow-up of Metaphyseal Sclerotic Lines in Children Treated with Pamidronate
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Bisphosphonates are widely used for the management steroid-induced osteoporosis (SIO) in children. With the increasing use of bisphosphonates, there have been reports of abnormal radiological findings in the growing skeleton. Therefore, their use in pediatric patients remains controversial. The present study was conducted to evaluate the long-term follow-up radiographic features, particularly metaphyseal sclerotic lines, in children who receive pamidronate therapy for nephropathy. Methods: Twenty-four children with nephropathy treated with oral calcium and pamidronate (mean duration, 9 months; dose, 100 mg daily), were evaluated retrospectively. All patients had SIO secondary to chronic glucocorticoid therapy for treating nephropathy. Long bone radiographic imaging was performed before treatment with pamidronate, and at follow-up, several years later. Physeal growth rates were estimated by measuring the distance that the sclerotic lines moved on the radiographs during the corresponding time intervals. Results: The mean follow-up period was 138 months. Long bone radiographs showed well-defined sclerotic lines at the metaphyseal ends, progressively moving from the physeal plate to the diaphysis, in all patients. The mean rate of movement of the sclerotic line was 6.21 mm per year. In 12 patients, the lines disappeared. The mean rate of growth in height was 7.33 cm per year. Conclusions: Results of long-term follow-up suggest that the metaphyseal sclerotic lines associated with pamidronate treatment tend to disappear without affecting overall skeletal growth. Bisphosphonate treatment for SIO in children with nephropathy seems to be safe, although further studies in larger number of patients are needed.
Abstract
Purpose: Bisphosphonates are widely used for the management steroid-induced osteoporosis (SIO) in children. With the increasing use of bisphosphonates, there have been reports of abnormal radiological findings in the growing skeleton. Therefore, their use in pediatric patients remains controversial. The present study was conducted to evaluate the long-term follow-up radiographic features, particularly metaphyseal sclerotic lines, in children who receive pamidronate therapy for nephropathy. Methods: Twenty-four children with nephropathy treated with oral calcium and pamidronate (mean duration, 9 months; dose, 100 mg daily), were evaluated retrospectively. All patients had SIO secondary to chronic glucocorticoid therapy for treating nephropathy. Long bone radiographic imaging was performed before treatment with pamidronate, and at follow-up, several years later. Physeal growth rates were estimated by measuring the distance that the sclerotic lines moved on the radiographs during the corresponding time intervals. Results: The mean follow-up period was 138 months. Long bone radiographs showed well-defined sclerotic lines at the metaphyseal ends, progressively moving from the physeal plate to the diaphysis, in all patients. The mean rate of movement of the sclerotic line was 6.21 mm per year. In 12 patients, the lines disappeared. The mean rate of growth in height was 7.33 cm per year. Conclusions: Results of long-term follow-up suggest that the metaphyseal sclerotic lines associated with pamidronate treatment tend to disappear without affecting overall skeletal growth. Bisphosphonate treatment for SIO in children with nephropathy seems to be safe, although further studies in larger number of patients are needed.
참고문헌 (20)
- Al Muderis M, "Zebra lines of pamidronate therapy in children", J Bone Joint Surg Am, 89, pp.1511~1516 (2007)
- Grissom LE, "Radiographic features of bisphosphonate therapy in pediatric patients", Pediatr Radiol, 33, pp.226~229 (2003)
- Rauch F, "Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis", J Bone Miner Res, 19, pp.1191~1193 (2004)
- Kim SD, "Pamidronate therapy for preventing steroidinduced osteoporosis in children with nephropathy", Nephron Clin Pract, 102, pp.81~87 (2006)
- Onwuneme C, "Radiological findings in cyclical administration of intravenous pamidronate in children with osteoporosis", Arch Dis Child, 92, pp.1087~ (2007)
- Suresh S, "Metaphyseal bands in osteogenesis imperfect", Indian J Radiol Imaging, 20, pp.42~44 (2010)
- Hong IK, "Scintigraphic findings of growth arrest lines after bisphosphonate administration in a steroid-induced osteoporosis patient: a case study", Clin Nucl Med, 35, pp.740~742 (2010)
- Devogelaer JP, "Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta", Skeletal Radiol, 16, pp.360~363 (1987)
- Samuel R, "Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher's disease", Pediatrics, 94, pp.385~389 (1994)
- Ogden JA, "Growth slowdown and arrest lines", J Pediatr Orthop, 4, pp.409~415 (1984)
- Lewiecki EM, "International Society for Clinical Densitometry: Official positions of the International Society for Clinical Densitometry", J Clin endocrinol Metab, 89, pp.3651~3655 (2004)
- Brumsen C, "Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis", Medicine (Baltimore), 76, pp.266~283 (1997)
- Fujiwara I, "Intravenous pamidronate treatment in osteogenesis imperfecta", Eur J Pediatr, 157, pp.261~262 (1998)
- Gonzalez E, "Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta", J Pediatr Endocrinol Metab, 14, pp.529~533 (2001)
- Sumnik Z, "Effect of pamidronate treatment on vertebral deformity in children with primary osteoporosis. A pilot study using radiographic morphometry", Horm Res, 61, pp.137~142 (2004)
- Barros ER, "Three years follow-up of pamidronate therapy in two brothers with osteoporosis-pseudoglioma syndrome (OPPG) carrying an LRP5 mutation", J Pediatr Endocrinol Metab, 21, pp.811~818 (2008)
- Glorieux FH, "Cyclic administration of pamidronate in children with severe osteogenesis imperfecta", N Engl J Med, 339, pp.947~952 (1998)
- Dimeglio LA, "A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta", J Pediatr Endocrinol Metab, 18, pp.43~53 (2005)
- Zacharin M, "Pamidronate treatment of osteogenesis imperfecta-- lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response", J Pediatr Endocrinol Metab, 15, pp.163~174 (2002)
- Silverman SL, "Rachitic syndrome after disodium etidronate therapy in an adolescent", Arch Phys Med Rehabil, 75, pp.118~120 (1994)